Palvella Therapeutics (PVLA) Share-based Compensation (2014 - 2026)

Palvella Therapeutics (PVLA) has 13 years of Share-based Compensation data on file, last reported at $51.6 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 4616.64% year-over-year to $51.6 million in Q1 2026; TTM through Mar 2026 was $51.6 million, a 2802.14% increase from a year earlier, with the FY2025 full-year figure at $30.1 million, up 183.96% from the prior year.
• Share-based Compensation for Q1 2026 stood at $51.6 million, up from $2.1 million in the prior quarter.
• Over the last five years, Share-based Compensation for PVLA reached as high as $51.6 million in Q1 2026 and fell as low as -$2.3 million in Q4 2023.
• Historically, Share-based Compensation has averaged $3.8 million across 5 years, with a median of $974000.0 in 2022.
• Across the five-year window, Share-based Compensation tumbled 341.83% in 2023 and surged 4616.64% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $949000.0 in 2022, then tumbled by 341.83% to -$2.3 million in 2023, then jumped by 111.68% to $268000.0 in 2024, then surged by 677.61% to $2.1 million in 2025, then surged by 2376.01% to $51.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $51.6 million in Q1 2026, $2.1 million in Q4 2025, and $1.8 million in Q3 2025.